Immunogenicity and Safety of Sabin-IPV Replacement Vaccination
a Randomized, Controlled Clinical Trial of Immunogenicity and Safety of Sabin-based Inactivated Polio Vaccine Replacing Salk-based Inactivated Polio Vaccine
Sponsor: Beijing Center for Disease Control and Prevention
Listed as NCT04051736, this PHASE4 trial focuses on Vaccination and remains completed. Sponsored by Beijing Center for Disease Control and Prevention, it has been updated 7 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE4
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
▶ Show 2 earlier versions
-
Dec 2019 — Oct 2020 [monthly]
Active Not Recruiting PHASE4
-
Sep 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE4
First recorded
Mar 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing Center for Disease Control and Prevention
- Beijing Institute of Biological Products Co Ltd.
- China National Biotec Group Company Limited
- Peking University
For direct contact, visit the study record on ClinicalTrials.gov .